About Profusa
Profusa is a company based in San Francisco (United States) founded in 2009. It operates as a HealthTech and Product-as-a-Service. Profusa has raised $64.92 million across 19 funding rounds from investors including Nasdaq, NIH and HHS. Profusa offers products and services including Lumee Oxygen Platform and Glucose Biosensors. Profusa operates in a competitive market with competitors including Theranica, Mainstay Medical, Sooma Oy, SPR Therapeutics and ZetrOZ, among others.
- Headquarter San Francisco, United States
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Profusa, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$64.92 M (USD)
in 19 rounds
-
Latest Funding Round
$45 M (USD), Series C
Aug 14, 2018
-
Investors
Nasdaq
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Profusa
Profusa offers a comprehensive portfolio of products and services, including Lumee Oxygen Platform and Glucose Biosensors.
Continuous tissue oxygen monitoring is enabled by this platform.
Glucose levels are monitored continuously with innovative biosensor technology.
Funding Insights of Profusa
Profusa has successfully raised a total of $64.92M across 19 strategic funding rounds. The most recent funding activity was a Series C round of $45 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Profusa
Profusa has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Nasdaq, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Science focused early & growth stage VC firm investing in the US & China
|
Locked | Locked | Locked | |
|
VC firm investing in geographies such as South Korea
|
Locked | Locked | Locked | |
|
Early-stage US companies are invested in by Asset Management Ventures.
|
Locked | Locked | Locked |
Investor details for Profusa
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Profusa
Investment portfolio details for Profusa
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Profusa
Detailed financials for Profusa
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Profusa Comparisons
Peer comparison for Profusa
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Profusa
Profusa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Theranica, Mainstay Medical, Sooma Oy, SPR Therapeutics and ZetrOZ, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for pain management are developed and manufactured.
|
|
| Locked | Locked | Locked |
Provider of rehabilitation solutions for patients and doctors
|
|
| Locked | Locked | Locked |
Non-invasive neuromodulation therapies
|
|
| Locked | Locked | Locked |
Pioneers non-invasive devices for chronic pain relief through medical innovation.
|
|
| Locked | Locked | Locked |
Wearable bioelectronic devices for acoustic medicine treatments are developed.
|
|
| Locked | Locked | Locked |
Wearable therapeutic fabrics for pain management are offered by Nufabrx.
|
Detailed competitors of Profusa
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Profusa
Complete news archive for Profusa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Profusa
Profusa was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Profusa is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Profusa is a funded company, having raised a total of $64.92M across 19 funding rounds to date.
Profusa, Inc. is engaged in the development of innovative tissue-integrating biosensors designed for continuous monitoring of body chemistries. The companys flagship product, the Lumee Oxygen Platform, is utilized for real-time tissue oxygen monitoring and has received CE Mark approval in the European Union. Additionally, glucose biosensors are being pioneered to expand monitoring capabilities. Solutions are targeted at healthcare applications, particularly in critical limb ischemia and influenza detection, with potential for telehealth and remote patient monitoring. Research and partnerships, including DARPA-backed studies, are leveraged to enhance early disease detection and improve clinical management in the medical sector.
Profusa's top competitors include Theranica, Mainstay Medical and Nufabrx.
Profusa offers Lumee Oxygen Platform and Glucose Biosensors.
Profusa has 11 investors. Key investors include Nasdaq, NIH, HHS, Atinum Investment, and SBIR.